Best Healthcare Companies in Occitanie, France
The 55 best Healthcare companies in Occitanie, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: CILcare.
Ranked: Best Healthcare companies in Occitanie
| # | Company | Last round | Disclosed funding | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AB7 Group Manufacturer of veterinary, cosmetic, and household products. | — | — | 34 | Rene Chelle Founder | WebflowTypekitGoogle Font API+11 | Top 10M | — | — |
| 2 | Alvina Provider of natural medicinal water for optimal digestive health, offering detox cures and constipation… | — | — | 1 | Eric Gauthier Founder & CEO | — | — | — | — |
| 3 | Amylgen Preclinical CRO providing specialized services for CNS diseases | — | — | — | Francois Roman Co-Founder | — | — | — | — |
| 4 | Antellis Company with expertise in ICP-MS based elemental analysis and offering analytical and impurity testing… | — | — | 4 | — | — | — | — | — |
| 5 | Arexan Provider of cybersecurity services encompassing awareness, design, management, and testing | — | — | — | Thierry Flocard Co-Founder & President | — | — | — | — |
| 6 | BYG4lab Provider of data management services for laboratories | — | — | 100 | Cyril Verhille Chairman & CEO | WordPressMySQLPHP+21 | Top 10M | — | — |
| 7 | Cardiomedex CRO offering its services to determine the cardiovascular effects of drug candidates | — | — | — | — | — | — | — | — |
| 8 | DiaDom Distributor of medical and surgical supplies | — | — | 70 | — | WordPressMySQLPHP+22 | Top 5M | — | 1 launch |
Top 12 Healthcare companies in Occitanie
#1
Series A · Toulouse, Occitanie · founded 2011 · 39 employees$8.8Mraised▾
Genoskin, founded as a spin-off of from the French National Center for Scientific Research (CNRS) and The Paul Sabatier University in Toulouse is engaged in the development of ex vivo human skin models for preclinical efficacy and toxicity testing of potential drug candidates and might help in reducing the use of lab animals. The company claims to keep real human skin tissue alive for 7 days in human skin models and that they are the closest alternative to in vivo clinical testing. The company claims that its human skin collection process is as per the Declaration of Helsinki. The company has a BSL 2 cell culture rooms and 3D imaging technologies. They have proprietary human skin models such as Oncoskin, which can be used to study melanoma and Hyposkin to study subcutaneous injections.
- Sep 2025Series A$5.4M
- Sep 2025Conventional Debt$3.3M
- Aug 2019Grant (prize money)—
- Nov 2018Grant (prize money)$56.9K
#2
Series A · Montpellier, Occitanie · founded 2014 · 28 employees$42.3Mraised▾
CILcare is an R&D services company specialised in the development of drug candidates for hearing disorders (tinnitus, hearing loss) and otic disorders (ENT). The company provides preclinical services for research and development related to the hearing disorders area.
- Dec 2024Series A$42.3M
#3
Series A · Montpellier, Occitanie · founded 2018$6Mraised▾
Standalone gynaecology clinic
- Jan 2024Series A$6M
#4
Acquired · Grabels, Occitanie · founded 2013 · 13 employees$4.7Mraised▾
BCI Pharma is a Contract Research Organisation offering services and products (new chemotypes) to increase the efficacy of drug discovery. BCI pharma runs projects mainly in cancer, neuropathic pain, inflammation and neuroinflammation (MS, Alzheimer, ALS). BCI Pharma chemical libraries include kinase libraries, macrocyclic peptide libraries. The company provides services such as library synthesis, medicinal chemistry services, and consultancy services.
- Mar 2018Series A$4.7M
#5
Seed · Toulouse, Occitanie · founded 2016 · 4 employees$1.6Mraised▾
Manufacturer of drugs for multiple therapeutic areas
- Mar 2021Seed$1.6M
#6
Seed · Toulouse, Occitanie · founded 2018 · 10 employees$1.2Mraised▾
Developer of swallow disorder management devices designed to change the way dysphagia is diagnosed and managed. The company's devices are backed by artificial intelligence which consists of a non-invasive, portable, and ergonomic collar equipped with sensors that detect swallowing, breathing, coughing, and voice signals, enabling medical professionals to enhance their daily work with patients suffering from dysphagia.
- Sep 2020Seed$1.2M
#7
Series A · Fabregues, Occitanie · founded 2009 · 2 employees$1.5Mraised▾
Provider of cryotherapy equipment and solutions for medical and sports applications. It offers various cryotherapy modalities, including water, gas, air, and compression-based systems. These solutions cater to post-operative care, sports recovery, dental, aesthetic, and equine applications. The company also provides equipment rental options and gas bottle reservations.
- Jul 2019Series A$1.5M
#8
Funding Raised · Toulouse, Occitanie · founded 2005$1.3Mraised▾
CDMO specializing in lentiviral vector manufacturing for gene and cell therapies. It provides viral vectors for research and clinical applications. The company offers services from discovery to clinical phases, supporting biotech companies in therapeutic development. It focuses on DNA and RNA delivery solutions for gene addition, gene editing, and immunotherapy. The company operates GMP-certified viral vector production suites and a fill & finish suite, adhering to regulatory requirements for starting materials and drug products.
- Jan 2020Grant (prize money)$1.3M
#9
Funding Raised · Toulouse, Occitanie · founded 2007 · 11 employees$1.5Mraised▾
Ambiotis is specialized in inflammation and its resolution. They are offering inflammatory assays, mediators and lipid analysis by mass spectrometry. The company has developed a step by step approach to anti-inflammation resolution strategies which includes in vitro screening of drug potential and in vivo proof-of-concept (disease models). The in vitro models include whole blood, monocytes, dendritic cells, macrophages, keratinocytes, fibroblasts, melanocytes, and others. In vivo models include respiratory disease, allergy, intestinal bowel disease, obesity, fibrosis, etc. They also provide analytical services including lipid analysis, gene expression, etc. The company also specializes in the valorization of nutritional and dermatological products.
- May 2018Grant (prize money)$747.3K
- Jan 2018Grant (prize money)$747.3K
#10
Funding Raised · Labege, Occitanie · founded 2002 · 21 employees$1.3Mraised▾
Physiogenex is a preclinical CRO that has expertise in metabolic disorders. The company maintains multiple animal models of diseases such as Type 2 diabetes (including nutritional models such as DIO rats and mice, HFD mice, HFD CETP-apoB100 (in-house transgenic), insulin resistant and dyslipidemic hamster, insulin resistant and insulin resistant hypertensive rats, and genetic models like ob/ob mouse, db/db mouse, Zucker Diabetic Fatty (ZDF) rats, ZFR and Goto-Kakizaki (GK) rat), Dyslipidemia/Atherosclerosis (including nutritional rat, mouse and hamster models - ApoE-KO and LDL-R KO mice, Insulin resistant and dyslipidemic hamsters, hypercholesterolemic hamsters), NASH (NASH mouse model, diet-induced NASH/liver fibrosis, NASH rat and hamster models, CCL4 induced NASH/fibrosis models), Obesity and Immunometabolic disorders (including a proprietary human-like mouse model in a context of immune, etc.
- Sep 2010Grant (prize money)$343.8K
- Sep 2006Grant (prize money)$46K
- Sep 2006Grant (prize money)$880.7K
#11
Funding Raised · Toulouse, Occitanie · founded 2017$339.9Kraised▾
Provider of genotoxicity and carcinogenicity assessment services for various industries. It supports clients in evaluating the genotoxic and potentially carcinogenic properties of their compounds, samples, or products. With expertise in genotoxicity studies, it offers personalized studies adapting to various compounds and human cell lines. The goal is to provide quality information to clients for R&D or quality control, respecting regulations and reducing animal use.
- Nov 2021Grant (prize money)$339.9K
#12
Acquired · Saint Gely du Fesc, Occitanie · founded 2010 · 294 employees$228.7Kraised▾
Amatsi Group was formed by the merger of several companies with expertise in in-vivo studies, bioanalysis, pharmaceutical analysis (Pierre Fabre, France), formulation development (SEPS Pharma, Belgium), process development and biomanufacturing (Q-Biologicals, Belgium), and clinical trial supply (packaging and logistics). The company also acquired Avogadro LS company, an animal health focussed company. The company has around 8 sites in the US, France, and Belgium for catering to the development of biologics across all stages of preclinical and clinical development. The company's service offerings are broadly categorized into 5 major segments namely: Biologicals (Mammalian and Microbial cell line based process development, Upstream and Downstream processing), Bioanalysis (in vivo studies, PK, ADME, Biomarker and assay development and validation studies etc.), Pharma analysis solutions (Analytical MD and MV, Stability studies etc.), Formulation Development and Manufacturing (Small Molecules, Amino acid, Peptide, Oligonucleotide, Plasmid vector, Interleukin, Protein, Immunoglobulin, Interferon, mAb, ADC, Inactivated bacteria etc.
- Dec 2017Grant (prize money)$228.7K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Healthcare coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.